Oct 21 2009
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues. The implied 1,000% possible increase is consistent with the 1,000% share price increase of the CI Index company furthest along in FDA trials, Dendreon (NASDAQ:DNDN). The share price increase followed Dendreon’s positive Phase III prostate cancer immunotherapy results during March 2009.
Two companies have lead the CI Index during the quarter in both growth and potential growth. ImmunoCellular Therapeutics, Inc. (IMUC.OB) was 1st in growth, and 2nd in remaining potential. Mentor Capital, Inc. (PINK SHEETS:MNTR) was 3rd in growth and 1st in potential market cap growth. In addition to ImmunoCellular Therapeutics, Mentor Capital and Dendreon, the CI Index features Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (PINK SHEETS:BVTI), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (NWBO.OB), CEL – SCI Corp. (AMEX:CVM), Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express. The Mentor Capital, Inc. value substantially tracks the value of its major investee, Quantum Immunologics, Inc., which is private.
In the cancer immunotherapy field, the goal is to train the patient’s immune system to recognize and attack cancer cells much the way the immune system naturally attacks any microbe. If efficacy can be firmly established, the slight temperature and feeling of tiredness accompanying any immune response is infinitely preferable to the debilitating effects of chemotherapy, radiation or surgeries. The weekly public market progress of the companies in the cancer immunotherapy sector can be followed in detailed updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.
http://www.mentorcapital.com/
Study shows AI can predict prognosis in triple-negative breast cancer